BUY | SELL | ||
---|---|---|---|
QTY | PRICE | PRICE | QTY |
20 | 334.00 | 342.70 | 25 |
198 | 333.10 | 343.50 | 42 |
62 | 333.00 | 345.00 | 42 |
10 | 332.85 | 346.90 | 15 |
10 | 332.00 | 348.00 | 5 |
0 | Total | Total | 0 |
As on 03 Feb, 2023 | 04:01
BUY | SELL | ||
---|---|---|---|
QTY | PRICE | PRICE | QTY |
20 | 334.00 | 342.70 | 25 |
198 | 333.10 | 343.50 | 42 |
62 | 333.00 | 345.00 | 42 |
10 | 332.85 | 346.90 | 15 |
10 | 332.00 | 348.00 | 5 |
0 | Total | Total | 0 |
Stock with good financial performance alongside good to expensive valuation
Open | 348.00 |
Previous Close | 348.10 |
Volume | 414,195.00 |
Value (Lacs) | 1,423.38 |
VWAP | 333.86 |
Beta |
High | 350.00 |
Low | 311.60 |
UC Limit | 417.70 |
LC Limit | 278.50 |
52 Week High | 595.95 |
52 Week Low | 281.80 |
TTM EPS See historical trend | 10.24 (-71.31% YoY) |
TTM PE See historical trend | 33.56 (High PE) |
P/B See historical trend | 1.03 (Low P/B) |
Face Value | 1.00 |
Mkt Cap (Rs. Cr.) | 5,474 |
Dividend Yield | 1.45 |
20D Avg Volume | 84,650 |
20D Avg Delivery(%) | 37.05 |
Sector PE | 27.21 |
Book Value Per Share | 333.78 |
*Delayed by 20 seconds.
Type | R1 | R2 | R3 | PP | S1 | S2 | S3 |
---|---|---|---|---|---|---|---|
Classic | - - | - - | - - | - - | - - | - - | - - |
Fibonacci | - - | - - | - - | - - | - - | - - | - - |
Camarilla | - - | - - | - - | - - | - - | - - | - - |
Note : Support and Resistance level for the day, calculated based on price range of the previous trading day.
R1 | - - | Pivot - - |
S1 | - - |
R2 | - - | S2 | - - | |
R3 | - - | S3 | - - |
Note : Support and Resistance level for the day, calculated based on price range of the previous trading day.
Days | |
---|---|
5 | - - |
10 | - - |
20 | - - |
50 | - - |
100 | - - |
200 | - - |
Type | R1 | R2 | R3 | PP | S1 | S2 | S3 |
---|---|---|---|---|---|---|---|
Classic | - - | - - | - - | - - | - - | - - | - - |
Fibonacci | - - | - - | - - | - - | - - | - - | - - |
Camarilla | - - | - - | - - | - - | - - | - - | - - |
Note : Support and Resistance level for the week, calculated based on price range of the previous trading week.
R1 | - - | Pivot - - |
S1 | - - |
R2 | - - | S2 | - - | |
R3 | - - | S3 | - - |
Note : Support and Resistance level for the week, calculated based on price range of the previous trading week.
Days |
---|
Type | R1 | R2 | R3 | PP | S1 | S2 | S3 |
---|---|---|---|---|---|---|---|
Classic | - - | - - | - - | - - | - - | - - | - - |
Fibonacci | - - | - - | - - | - - | - - | - - | - - |
Camarilla | - - | - - | - - | - - | - - | - - | - - |
Note : Support and Resistance level for the month, calculated based on price range of the previous trading month.
R1 | - - | Pivot - - |
S1 | - - |
R2 | - - | S2 | - - | |
R3 | - - | S3 | - - |
Note : Support and Resistance level for the month, calculated based on price range of the previous trading month.
Days |
---|
1 Week | --% | |
1 Month | --% | |
3 Months | --% | |
YTD | --% | |
1 Year | --% | |
3 Years | --% |
Jubilant Pharmo Standalone December 2022 Net Sales at Rs 182.74 crore, up 878.79% Y-o-Y Feb 04 2023 12:02 AM
Trade Spotlight | What should you do with Jubilant Pharmova, Tube Investments of India, Varun Beverages on Monday? Dec 12 2022 06:12 AM
Hold Jubilant Pharmova; target of Rs 395: ICICI Direct Nov 01 2022 06:11 PM
Trade Spotlight | What should you do with Aegis Logistics, Jubilant Pharmova, Cummins India on Monday? Oct 31 2022 06:10 AM
Qty 683197 | Price 313.3 | % Traded 0.43 |
Qty 84898 | Price 313.3 | % Traded 0.05 |
Qty 683197 | Price 313.3 | % Traded 0.43 |
Qty 84898 | Price 313.3 | % Traded 0.05 |
Qty 250000 | Price 617 | % Traded 0.16 |
Qty 250000 | Price 617 | % Traded 0.16 |
Qty 2500000 | Price 594.35 | % Traded 1.57 |
Qty 2000000 | Price 594.35 | % Traded 1.26 |
*Transaction of a minimum quantity of 500,000 shares or a minimum value of Rs 5 crore.
Qty 2500000 | Price 594.35 | % Traded 1.57 |
Qty 2000000 | Price 594.35 | % Traded 1.26 |
Qty 4025000 | Price 594.35 | % Traded 2.53 |
Qty 2405583 | Price 497.6 | % Traded 1.51 |
Qty 1626012 | Price 495.75 | % Traded 1.02 |
Qty 1160000 | Price 493 | % Traded 0.73 |
Qty 2013626 | Price 436.23 | % Traded 1.27 |
Qty 1250000 | Price 435 | % Traded 0.79 |
*A bulk deal is a trade where total quantity of shares bought or sold is more than 0.5% of the equity shares of a company listed on the exchange.
Qty 20112 | Price 377.7 | % Traded 0.01 | Post Tnx Hold. 0.13% |
Qty 8925 | Price 378.14 | % Traded 0.01 | Post Tnx Hold. 0.12% |
Qty 2500 | Price 378.1 | % Traded 0.00 | Post Tnx Hold. 0.11% |
Qty 5252 | Price 378.85 | % Traded 0.00 | Post Tnx Hold. 0.11% |
Qty 50988 | Price 378.52 | % Traded 0.03 | Post Tnx Hold. 0.11% |
Qty 10209 | Price 378.35 | % Traded 0.01 | Post Tnx Hold. 0.07% |
*Disclosures under SEBI Prohibition of Insider Trading Regulations, 2015
Qty 0 | Price 0 | % Traded 0.00 | Post Tnx Hold. 0% |
Qty 62943636 | Price 0 | % Traded 39.52 | Post Tnx Hold. 50.68% |
Qty 0 | Price 0 | % Traded 0.00 | Post Tnx Hold. 0% |
Qty 62943636 | Price 0 | % Traded 39.52 | Post Tnx Hold. 50.68% |
Qty 600800 | Price 0 | % Traded 0.37 | Post Tnx Hold. 5.18% |
Qty 1157078 | Price 0 | % Traded 0.73 | Post Tnx Hold. 8% |
*Disclosures under SEBI SAST (Substantial Acquisition of Shares and Takeovers) Regulations, 2011
Date | Agenda |
---|
Ex-Date | Type | Dividend (Rs) |
---|
Announcement Date | Ex-Bonus | Ratio |
---|
Ex-Split | Old FV | New FV |
---|
Ex-Right | Ratio | Premium |
---|
Date | Agenda |
---|
Company Name | Price | % Chg | MCap(Cr) | TTM PE | P/B | ROE(%) | 1 Yr Perform(%) | Net Profit(Rs.) | Net Sales(Rs.) | Debt to Equity |
---|---|---|---|---|---|---|---|---|---|---|
Jubilant Pharmo | 343.65 | -1.28 | 5,473.70 | 33.56 | 1.03 | 7.78 | -34.46 | 423 | 6,130 | 0.55 |
Sun Pharma | 1,028.15 | 2.04 | 246,687.62 | 58.58 | 4.83 | 6.81 | 16.37 | 3,405 | 38,654 | 0.02 |
Cipla | 1,022.30 | -0.29 | 82,514.32 | 31.27 | 3.91 | 12.07 | 7.30 | 2,559 | 21,763 | 0.04 |
Divis Labs | 2,884.35 | -11.71 | 76,570.43 | 25.59 | 6.53 | 25.24 | -32.33 | 2,960 | 8,959 | 0.00 |
Dr Reddys Labs | 4,358.35 | -0.27 | 72,576.83 | 19.92 | 3.78 | 11.35 | -0.37 | 2,112 | 21,545 | 0.16 |
Your feedback matters! Tell us what we got right and what we didn’t? Click here>